LEROY PHARMACIES, NYC NINE-STORE CHAIN, AIMS AT AIDS PATIENTS and the critically ill market by piggybacking pharmacy services with home medical equipment operations, the New York City-based drugstore chain noted in a recent filing with the Securities & Exchange Commission. The filing details the chain's $ 3.2 mil. initial public offering. "The company believes that its ability to deliver both home medical equipment and pharmaceuticals is of particular importance to the to the critically ill, who need large doses of pharmaceuticals not widely used by the general population," the filing states. "This integration . . . gives the company a competitive advantage over other medical equipment suppliers in the New York City area." The chain's expanding home health care business is based on government and private insurer reimbursement policies that favor home health care over extended hospitalization, an aging U.S. population and a growing number of AIDS patients in the New York area. Leroy Pharmacies currently operates nine outlets -- eight in Manhattan, one in the Bronx -- and has plans to open two additional Manhattan locations within 18 months after the offering. Home health makes up a relatively small part of Leroy's total business. The filing notes that home health comprised 5% of the chain's $ 23.2 mil. revenues in 1987 and 7.7% of the $ 13.4 mil. sales volume reported for the first six months of 1988. The company earned $ 456.000 and $ 301,000 for the 12-month and six-month periods, respectively. In addition, Leroy noted, current home medical equipment customers have not been, for the most part, customers of the drugstores. Through its Accuhealth subsidiary, the chain has contracts with five hospices in the New York area and is an "approved provider" of home health services for 20 New York City hospitals. Expansion of Accuhealth following the offering will include a move into the areas of total parenteral nutrition and apnea monitoring. "The company plans to market its TPN and pediatric critical care through contracts with services which connect and maintain the intravenous lines and apnea monitoring equipment," the filing states. "The company also expects that these businesses will be dependent upon referrals from hospitals, ouptatient services and other extended care facilities." The company follows a neighborhood drugstore concept under which store layouts, shelf space allocations and merchandising displays are based on the purchasing patterns of a given community. Stanley Lepelstat is the chain's founder and chairman. The 700,000 unit common stock/warrant offering, which is being managed by Whale Securities, will reduce Lepelstat's equity in the chain from 93% to 56%.
Join thousands of industry professionals who rely on Pink Sheet for daily insights
Already a subscriber?
Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.
This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.
A new pilot aims to take Brazil closer to ‘digital transformation.’
Office of Therapeutic Products Director Nicole Verdun and her deputy Rachael Anatol were escorted out of FDA headquarters on June 18. Disagreements over CAR-T regulation and Capricor’s DMD treatment may be to blame.
As Chief Medical and Scientific Officer, Vinay Prasad will advise the FDA Commissioner on cross-cutting issues, provide strategic leadership and be a public face of the agency.
Eisai and Lilly explain why they disagree with today’s conclusion by the health technology assessment institute, NICE, that the benefits of their respective drugs for Alzheimer’s disease are too small to justify the additional cost to the National Health Service.
